Metabolomic profiling of pancreatic adenocarcinoma reveals key features driving clinical outcome and drug resistance

Metabolomic profiling of pancreatic adenocarcinoma reveals key features driving clinical outcome and drug resistance

Background: Although significant advances have been made recently to characterize the biology of pancreatic ductal adenocarcinoma (PDAC), more efforts are needed to improve our understanding and to face challenges related to the aggressiveness, high mortality rate and chemoresistance of this disease...

Full description

Bibliographic Details
Main Authors: Abdessamad El Kaoutari, Nicolas A. Fraunhoffer, Owen Hoare, Carlos Teyssedou, Philippe Soubeyran, Odile Gayet, Julie Roques, Gwen Lomberk, Raul Urrutia, Nelson Dusetti, Juan Iovanna
Format: Article
Language:English
Published: Elsevier 2021-04-01
Series:EBioMedicine
Subjects:
Pancreatic cancer
Metabolomics
Chemosensitivity
Tumor heterogeneity
Metabolic signature
Precision medicine
Online Access:http://www.sciencedirect.com/science/article/pii/S2352396421001250

Internet

http://www.sciencedirect.com/science/article/pii/S2352396421001250

Similar Items